These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

501 related articles for article (PubMed ID: 33829580)

  • 1. Analysis of Real-World Data to Investigate the Impact of Race and Ethnicity on Response to Programmed Cell Death-1 and Programmed Cell Death-Ligand 1 Inhibitors in Advanced Non-Small Cell Lung Cancers.
    Ayers KL; Mullaney T; Zhou X; Liu JJ; Lee K; Ma M; Jones S; Li L; Redfern A; Jappe W; Liu Z; Goldsweig H; Yadav KK; Hahner N; Dietz M; Zimmerman M; Prentice T; Newman S; Veluswamy R; Wisnivesky J; Hirsch FR; Oh WK; Li SD; Schadt EE; Chen R
    Oncologist; 2021 Jul; 26(7):e1226-e1239. PubMed ID: 33829580
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-World Outcomes for Advanced Non-Small Cell Lung Cancer Patients Treated With a PD-L1 Inhibitor Beyond Progression.
    Stinchcombe TE; Miksad RA; Gossai A; Griffith SD; Torres AZ
    Clin Lung Cancer; 2020 Sep; 21(5):389-394.e3. PubMed ID: 32409266
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world data prognostic model of overall survival in patients with advanced NSCLC receiving anti-PD-1/PD-L1 immune checkpoint inhibitors as second-line monotherapy.
    Julian C; Machado RJM; Girish S; Chanu P; Heinzmann D; Harbron C; Gershon A; Pfeiffer SM; Zou W; Quarmby V; Zhang Q; Chen Y
    Cancer Rep (Hoboken); 2022 Oct; 5(10):e1578. PubMed ID: 35075804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Very high PD-L1 expression as a prognostic indicator of overall survival among patients with advanced non-small cell lung cancer receiving anti-PD-(L)1 monotherapies in routine practice.
    Shah M; Hubbard RA; Mamtani R; Marmarelis ME; Hennessy S
    Pharmacoepidemiol Drug Saf; 2022 Oct; 31(10):1121-1126. PubMed ID: 35670103
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pembrolizumab for Previously Treated, PD-L1-expressing Advanced NSCLC: Real-world Time on Treatment and Overall Survival.
    Velcheti V; Chandwani S; Chen X; Piperdi B; Burke T
    Clin Lung Cancer; 2020 Sep; 21(5):e445-e455. PubMed ID: 32376116
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Real-world study on the efficacy and prognostic predictive biomarker of patients with metastatic non-small cell lung cancer treated with programmed death-1/programmed death ligand 1 inhibitors].
    Zhu WJ; Zhu HH; Liu YT; Lin L; Xing PY; Hao XZ; Cong MH; Wang HY; Wang Y; Li JL; Feng Y; Hu XS
    Zhonghua Zhong Liu Za Zhi; 2022 May; 44(5):416-424. PubMed ID: 35615798
    [No Abstract]   [Full Text] [Related]  

  • 7. Real-World Outcomes of Patients With Advanced Non-small Cell Lung Cancer Treated With Anti-PD1 Therapy on the Basis of PD-L1 Results in EBUS-TBNA vs Histological Specimens.
    Tajarernmuang P; Ofiara L; Beaudoin S; Wang H; Benedetti A; Gonzalez AV
    Chest; 2021 Aug; 160(2):743-753. PubMed ID: 33675792
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of efficacy and safety between PD-1 inhibitors and PD-L1 inhibitors plus platinum-etoposide as first-line treatment for extensive-stage small-cell lung cancer: a multicenter, real-world analysis.
    Wang Y; Li L; Hu J; Zhao Y; Yan H; Gao M; Yang X; Zhang X; Ma J; Dai G
    BMC Cancer; 2023 Dec; 23(1):1196. PubMed ID: 38057736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer.
    Assoun S; Theou-Anton N; Nguenang M; Cazes A; Danel C; Abbar B; Pluvy J; Gounant V; Khalil A; Namour C; Brosseau S; Zalcman G
    Lung Cancer; 2019 Jun; 132():65-71. PubMed ID: 31097096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The relative and absolute benefit of programmed death receptor-1 vs programmed death ligand 1 therapy in advanced non-small-cell lung cancer: A systematic review and meta-analysis.
    Yi K; Zhu Q; Kuang YK; Jiang SC; Hu H
    Int Immunopharmacol; 2020 Oct; 87():106852. PubMed ID: 32759049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-World Outcomes of Patients with Metastatic Non-Small Cell Lung Cancer Treated with Programmed Cell Death Protein 1 Inhibitors in the Year Following U.S. Regulatory Approval.
    Khozin S; Carson KR; Zhi J; Tucker M; Lee SE; Light DE; Curtis MD; Bralic M; Kaganman I; Gossai A; Hofmeister P; Torres AZ; Miksad RA; Blumenthal GM; Pazdur R; Abernethy AP
    Oncologist; 2019 May; 24(5):648-656. PubMed ID: 30591549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early on-treatment tumor growth rate (EOT-TGR) determines treatment outcomes of advanced non-small-cell lung cancer patients treated with programmed cell death protein 1 axis inhibitor.
    He LN; Fu S; Ma H; Chen C; Zhang X; Li H; Du W; Chen T; Jiang Y; Wang Y; Wang Y; Zhou Y; Lin Z; Yang Y; Huang Y; Zhao H; Fang W; Zhang H; Zhang L; Hong S
    ESMO Open; 2022 Dec; 7(6):100630. PubMed ID: 36442353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy.
    Ferrara R; Mezquita L; Texier M; Lahmar J; Audigier-Valette C; Tessonnier L; Mazieres J; Zalcman G; Brosseau S; Le Moulec S; Leroy L; Duchemann B; Lefebvre C; Veillon R; Westeel V; Koscielny S; Champiat S; Ferté C; Planchard D; Remon J; Boucher ME; Gazzah A; Adam J; Bria E; Tortora G; Soria JC; Besse B; Caramella C
    JAMA Oncol; 2018 Nov; 4(11):1543-1552. PubMed ID: 30193240
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-World Outcomes and Prognostic Factors Among Patients with Advanced Non-Small Cell Lung Cancer and High PD-L1 Expression Treated with Immune Checkpoint Inhibitors as First-Line Therapy.
    Ge W; Wu N; Jalbert JJ; Quek RGW; Liu J; Rietschel P; Pouliot JF; Harnett J; Hsu ML; Feliciano JL
    Cancer Manag Res; 2022; 14():3191-3202. PubMed ID: 36415537
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-intensity statins are associated with improved clinical activity of PD-1 inhibitors in malignant pleural mesothelioma and advanced non-small cell lung cancer patients.
    Cantini L; Pecci F; Hurkmans DP; Belderbos RA; Lanese A; Copparoni C; Aerts S; Cornelissen R; Dumoulin DW; Fiordoliva I; Rinaldi S; Aerts JGJV; Berardi R
    Eur J Cancer; 2021 Feb; 144():41-48. PubMed ID: 33326868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of Acetaminophen Exposure on Outcomes of Patients Receiving Immune Checkpoint Inhibitors for Advanced Non-Small-Cell Lung Cancer: A Propensity Score-Matched Analysis.
    Nelli F; Virtuoso A; Giannarelli D; Fabbri A; Giron Berrios JR; Marrucci E; Fiore C; Ruggeri EM
    Curr Oncol; 2023 Sep; 30(9):8117-8133. PubMed ID: 37754504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characteristics of Real-World Metastatic Non-Small Cell Lung Cancer Patients Treated with Nivolumab and Pembrolizumab During the Year Following Approval.
    Khozin S; Abernethy AP; Nussbaum NC; Zhi J; Curtis MD; Tucker M; Lee SE; Light DE; Gossai A; Sorg RA; Torres AZ; Patel P; Blumenthal GM; Pazdur R
    Oncologist; 2018 Mar; 23(3):328-336. PubMed ID: 29317551
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trends in real-world biomarker testing and overall survival in US patients with advanced non-small-cell lung cancer.
    Wu N; Ge W; Quek RG; Gleeson M; Pouliot JF; Dietz H; Jalbert JJ; Harnett J; Antonia SJ
    Future Oncol; 2022 Dec; 18(39):4385-4397. PubMed ID: 36656547
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials.
    Borghaei H; Langer CJ; Paz-Ares L; Rodríguez-Abreu D; Halmos B; Garassino MC; Houghton B; Kurata T; Cheng Y; Lin J; Pietanza MC; Piperdi B; Gadgeel SM
    Cancer; 2020 Nov; 126(22):4867-4877. PubMed ID: 32914866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determining the optimal PD-1/PD-L1 inhibitors for the first-line treatment of non-small-cell lung cancer with high-level PD-L1 expression in China.
    Teng MM; Chen SY; Yang B; Wang Y; Han RY; An MN; Dong YL; You HS
    Cancer Med; 2021 Sep; 10(18):6344-6353. PubMed ID: 34382361
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.